| Name | Title | Contact Details |
|---|
Thirty Madison exists to deliver on healthcare`s biggest opportunities: access and affordability; patient outcomes; and patient experience. With empathy at the heart of its innovation, its proprietary care model empowers hundreds of thousands of people with ongoing conditions with accessible, effective treatments across a lifetime of care.
Inteleso is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Healthcare of Today is a Burbank, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
At VSP Global, we activate the full power of care by consciously reinvesting in greater vision, health, and opportunities for all. Our mission is to help people see every possibility—and we do that through our strategic business pillars that work together to connect nearly 90 million patients to network doctors in a variety of settings across the globe. When you become a VSPeep, you join a group of thinkers, doers, adventurers, risk-takers, and boundary pushers who think outside the peripheral to develop products, programs, and services that help create a world where everyone can bring their best vision to life. The VSP Global Values are: We care, We trust, We empower diversity, and We are one team. Join the power of our purpose and check out job opportunities with VSP Global and its strategic businesses, including: VSP Vision Care, Marchon Eyewear, Altair Eyewear, VSP Optics, Eyefinity EHR, VSP Retail, VSP Ventures, and Eyes of Hope (our charitable giving platform).
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.